The Angiotensine II type I receptor (AT1R) is the key mediator of these adverse effects and therefore silencing gene expression of AT1R using small interfering RNA (siRNA) is one of the best choices in order to restore blood pressure, prevent fibrosis and improve cardiac function after MI. This evidence concerns the gene AGTR1 and myocardial infarction.